The difference between information and
expert, data-driven actionable intelligence

 

October 2016

Welcome to the October 2016 issue of CMC Market Outlook

This monthly e-newsletter provides valuable insights for both buyers and sellers of CMC drug development services. Our coverage will help you identify and understand market trends that will inform your strategic business perspective.

Enjoy the October issue!

The PharmSource Team

 

Peptide API Market Growth Expected to Continue

CMOs with existing expertise in and capacity for development and manufacture of peptide drugs may find themselves uniquely positioned to take advantage of a surge in interest in such products. As the ability to synthesize these products grows and more dosage forms become available, more companies are adding peptide products-including potential biosimilars as some of the earliest patents expire-to their pipelines.

Since it takes time and money to develop sufficient expertise and add the necessary equipment to make these products, companies that don’t already have in-house capacity will likely turn to… read on
 

Contract Manufacturers Match Capabilities to Market Needs

by Jim Miller, President

While industry participants and observers talk about the “CMO industry,” they know that it is not an undifferentiated mass of manufacturers. The contract manufacturing organization (CMO) industry can be segmented along obvious lines such as API versus drug product manufacturers, biologics versus small molecule, dose form(s) manufactured, and geographic focus.

But none of these designations reflect the strategies that each CMO is pursuing, and without that basic understanding, one cannot fully understand the prospects for the industry… read on
 

Pharma Industry Interest in Colombia Remains Despite Civil Unrest, Regulatory Issues

Moving from an emerging economy into a major Latin America hub, Colombia has seen growing interest from pharmaceutical companies since about 2010. However, some regulatory concerns, as well as political unrest, seem to have put a slight damper on that interest, with fewer companies building or buying in the country.

The Colombian economy has been quite strong in recent years, as it evolves from an emerging economy, said Jason Miles, an analyst in the office of the US Trade Representative. Colombia boasts the fourth-largest economy in Latin America-with Brazil, Mexico and Argentina holding the top three spots-along with… read on
 

Bio/Pharma Sponsor Spending on In-house Manufacturing Capacity Soars

This data-rich report, Bio/Pharma CapEx Trends 2016, identifies 3 indicators of what’s ahead for your business:

1. Captive capacity remains the largest impediment to faster growth of the contract manufacturing and development industry.

2. Bio/pharma companies have invested over $150 billion for new plant and equipment in the past 5 years.

3. Based on recent capital expenditure trends, learn why bio/pharma companies would rather “make than buy.”


 

Celebrating 20 Years in Business!

Thank you to our clients, colleagues and friends. We look forward to many more years of successful business together.
 

PharmSource Strategic Advantage


Let PharmSource be your market intelligence guide.

PharmSource’s STRATEGIC ADVANTAGE service is the industry’s most respected outsourcing information web portal for serious consumers of information on contract drug development and manufacturing. Developed from PharmSource’s expert proprietary research, you won’t find this information in any other resource.

See for yourself how this resource gives you vital tools for understanding the industry.

To request a test-drive today, contact Nathaniel Celentano at nathaniel@pharmsource.com / +1-703-383-4903, ext. 112 (ET USA).